B4GALNT2 and colorectal carcinoma: Indeed, B4GALNT2 promoter methylation was observed in gastric cancer cases and in the majority of gastric and CRC cell lines analyzed in the Kawamura and collaborators studies.[37] However, anti‐DNA methylation treatment in cell lines with the methylation inhibitor 5‐aza‐2’‐deoxycytidine could induce only a weak expression of the B4GALNT2 gene and Sda antigen in these cells[37a] indicating that other regulatory mechanisms are likely involved.